創薬における人工知能/AI市場:オファリング、プロセス(ターゲット選択、バリデーション、リード生成、最適化)、ドラッグデザイン(低分子、ワクチン、抗体、PK/PD)、ドライラボ、ウェットラボ(シングルセル解析)、地域別 - 2028年までの世界予測Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028 創薬における人工知能(AI)市場は、予測期間中の年平均成長率40.2%で、2023年の9億米ドルから2028年には49億米ドルに達すると予測されている。AIは、複雑な生物学的データを分析することで、潜在的な創薬ターゲ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー創薬における人工知能(AI)市場は、予測期間中の年平均成長率40.2%で、2023年の9億米ドルから2028年には49億米ドルに達すると予測されている。AIは、複雑な生物学的データを分析することで、潜在的な創薬ターゲットの特定と検証を迅速化する。これにより、治療介入のための生物学的に関連性の高い標的の選択が加速される。機械学習などのAI技術は迅速な分析と意思決定を可能にし、創薬プロセスに必要な時間とリソースを削減する。この効率化により、ペースの速い医薬品業界において競争力を獲得することができる。したがって、前述の要因がこの市場の成長を促進する。一方、熟練労働者の不足は、予測期間中、市場の成長をある程度抑制する主要因である。"サービス分野は2022年に主要シェアを占めると推定され、また予測期間中に最も高い成長が見込まれる" 提供に基づき、創薬AI市場はソフトウェアとサービスに二分される。2022年の世界の創薬AIサービス市場では、ソフトウェアとサービスが最大の市場シェアを占め、予測期間中の年平均成長率も最も高くなると予測されている。サービスを通じてAI技術や専門知識にアクセスできるため、製薬企業が創薬にAIを導入する障壁が低くなる。これは、社内に広範なAI能力を持たない中小企業にとって特に有益であり、多額の先行投資を行うことなくAIの力を活用することを可能にする。 "創薬AI世界市場では機械学習技術分野が最大シェアを占める" 技術に基づき、創薬AI市場は機械学習、自然言語処理(NLP)、コンテキスト認識処理、その他の技術に区分される。機械学習分野は2022年に世界市場で最大のシェアを占め、予測期間中に最も高いCAGRで成長すると予測されている。機械学習は、潜在的な医薬品候補の人体内での挙動を予測する予測モデルの作成を可能にする。これは、成功の可能性が最も高い化合物を特定するのに役立ち、失敗した候補に関連するコストと時間を削減する。機械学習は、患者データを分析して薬剤に対する個々の反応を予測することで、個別化治療戦略の開発に貢献する。これにより、遺伝子情報、分子情報、臨床情報に基づいて治療法を調整することが容易になり、より効果的な転帰をもたらすとともに、創薬プロセスの加速に役立つことが、このセグメントの市場成長を支える要因の一部となっている。 "2022年、低分子設計・最適化分野がユースケース分野で最大シェアを占める見込み" ユースケースに基づき、創薬AI市場は、低分子設計・最適化、疾患・安全性・毒性の理解、ワクチン設計・最適化、抗体・その他生物製剤設計・最適化に分けられる。2022年には、低分子設計・最適化分野が創薬AI市場で最大のシェアを占めた。AIは主に2つの目的で低分子化合物の設計と最適化に使用される。第一に、既存の化学ライブラリーをスクリーニングしたり、ジェネレイティブ・デ・ノボ・デザインによって、ヒット化合物やリード化合物を同定するのに役立つ。第二に、AIは同定されたヒット化合物を最適化し、結合親和性、毒性、合成などの有利な特性を確保し、最終的に、より効果的で安全な医薬品候補の開発につなげる。これらの要素は、創薬のユースケースに合わせたAIアルゴリズムの開発と改良に貢献している。 "北米が2022年に創薬AI市場を支配する" 世界の創薬AI市場は、北米、欧州、APAC、その他の地域の4つの主要地域に区分される。2022年、北米は創薬AIで最大かつ最も急成長している地域市場を占めている。北米には、創薬におけるAIの能力を積極的に探求している数多くの製薬大手やバイオテクノロジー・イノベーターが存在する。これらの業界大手はAI主導の研究開発に多額の投資を行っており、市場成長を牽引している。北米では医薬品とヘルスケアに関する規制の枠組みが確立されているため、業界標準とガイドラインの遵守を確保しながらAI技術の統合を促進することができる。以上のような要因が、北米における創薬AI市場を牽引する。 供給側、需要側、一次インタビューの内訳、企業タイプ別、呼称別、地域別 - 企業タイプ別 - 供給サイド別ティア1(31%)、ティア2(28%)、ティア3(41) - 需要サイド別購買マネージャー(45%)、人工知能、機械学習、創薬、計算分子設計の責任者(30%)、研究科学者(25%)。 - 役職別Cレベル(31%)、ディレクターレベル(25%)、その他(44%) - 地域別北米(45%)、欧州(20%)、アジア太平洋(28%)、南米(4%)、中東・アフリカ(3%) 同市場における主要企業は、NVIDIA Corporation(米国)、Exscientia(英国)、BenevolentAI(英国)、Recursion(米国)、Insilico Medicine(米国)、Schrödinger, Inc.(米国)、Microsoft Corporation(米国)、Google(米国)、Atomwise Inc.(米国)、Illumina, Inc.(米国)、NuMedii, Inc.(米国)、XtalPi Inc.(米国)、Iktos(フランス)、Tempus Labs(米国)、Deep Genomics, Inc.(カナダ)、Verge Genomics社(米国)、BenchSci社(カナダ)、Insitro社(米国)、Valo Health社(米国)、BPGbio社(米国)、IQVIA社(米国)、Labcorp社(米国)、Tencent Holdings Limited社(中国)、Predictive Oncology, Inc.(米国)、Celsius Therapeutics(米国)、CytoReason(イスラエル)、Owkin, Inc.(米国)、Cloud Pharmaceuticals(米国)、Evaxion Biotech(デンマーク)、Standigm(韓国)、BIOAGE(米国)、Envisagenics(米国)、Aria Pharmaceuticals, Inc.各社は、製品の上市や機能強化、投資、提携、共同事業、資金調達、買収、拡大、契約、販売契約、提携などの有機的および無機的な成長戦略を採用し、提供製品を増やし、顧客の満たされていないニーズに対応し、収益性を高め、世界市場でのプレゼンスを拡大している。 調査範囲 - 当レポートでは、創薬AI市場を提供、技術、治療分野、ユースケース、プロセス、エンドユーザー、地域に基づいて調査しています。 - 市場成長に影響を与える要因(促進要因、阻害要因、機会、課題など)を分析しています。 - 関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。 - 当レポートでは、創薬AI市場の成長動向、将来性、市場全体への貢献に関してミクロ市場を調査しています。 - 主要5地域に関して市場セグメントの収益を予測しています。 レポート購入の理由 本レポートは、既存企業だけでなく、新規参入企業や小規模企業が市場の動向を把握するのに役立ち、ひいては、より大きなシェアを獲得するのに役立つでしょう。本レポートを購入される企業は、以下の5つの戦略を1つまたは組み合わせて使用することができます。 本レポートは、以下のポイントに関する洞察を提供する: 創薬AI市場の成長に影響を与える主要な促進要因(業界を超えたコラボレーションやパートナーシップの増加、創薬・開発コストの抑制と医薬品開発にかかる時間の短縮に対するニーズの高まり、複数の医薬品の特許切れ)、阻害要因(AI人材の不足、医療用ソフトウェアに関する曖昧な規制ガイドライン)、機会(成長するバイオテクノロジー産業、新興市場、人間を認識するAIシステムの開発に注力、COVID-19パンデミックにもかかわらず医薬品・生物製剤市場の成長)、課題(データセットの限られた利用可能性)の分析。 製品開発/イノベーション:創薬AI市場における今後の技術、研究開発活動、製品発売に関する詳細な洞察。 市場開発:有利な新興市場に関する包括的情報。本レポートでは、地域別に様々なタイプの創薬AIソリューションの市場を分析しています。 市場の多様化:創薬AI市場における製品、未開拓地域、最近の開発、投資に関する情報を網羅。 競合評価:創薬AI市場における主要企業の市場シェア、戦略、製品、流通網、製造能力を詳細に評価。 目次1 INTRODUCTION 381.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION 38 1.2.1 INCLUSIONS AND EXCLUSIONS 39 1.3 MARKET SCOPE 40 1.3.1 MARKET SEGMENTATION 40 FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION 40 1.3.2 REGIONAL SCOPE 41 1.3.3 YEARS CONSIDERED 41 1.3.4 CURRENCY CONSIDERED 42 TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 42 1.4 STAKEHOLDERS 42 1.5 SUMMARY OF CHANGES 43 1.5.1 RECESSION IMPACT 44 2 RESEARCH METHODOLOGY 45 2.1 RESEARCH DATA 45 FIGURE 2 RESEARCH DESIGN 45 2.2 SECONDARY SOURCES 46 2.2.1 KEY DATA FROM SECONDARY SOURCES 47 2.3 PRIMARY DATA 47 2.3.1 PRIMARY SOURCES 48 2.3.1.1 Key data from primary sources 49 2.3.1.2 Key industry insights 50 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 50 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION 50 2.4 MARKET SIZE ESTIMATION 51 FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 52 FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY 53 TABLE 2 FACTOR ANALYSIS 55 FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 56 FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 56 FIGURE 8 TOP-DOWN APPROACH 57 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 58 FIGURE 9 DATA TRIANGULATION METHODOLOGY 58 2.6 ASSUMPTIONS 59 2.6.1 MARKET SIZING ASSUMPTIONS 59 2.6.2 OVERALL STUDY ASSUMPTIONS 59 2.7 LIMITATIONS 60 2.8 RISK ASSESSMENT 60 TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET 60 2.9 RECESSION IMPACT ANALYSIS 61 TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 61 TABLE 5 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61 TABLE 6 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 62 3 EXECUTIVE SUMMARY 63 FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION) 63 FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 64 FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 64 FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 65 FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2023 VS. 2028 (USD MILLION) 66 FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 66 FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT 67 4 PREMIUM INSIGHTS 68 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET 68 FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET 68 4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE 69 FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD 69 4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69 FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028 69 4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022 70 FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022 70 4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING 70 FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028 70 4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 71 FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028 71 4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 71 FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028 71 4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS 72 FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028 72 4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE 72 FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD 72 4.10 AI IN DRUG DISCOVERY MARKET, BY END USER 73 FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028 73 5 MARKET OVERVIEW 74 5.1 INTRODUCTION 74 5.2 MARKET DYNAMICS 74 FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS 74 TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS 75 5.2.1 DRIVERS 75 5.2.1.1 Growing cross-industry collaborations and partnerships 75 TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021−2023) 76 5.2.1.2 Growing need to reduce time and cost of drug discovery and development 77 5.2.1.3 Patent expiry of several drugs 77 TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 78 5.2.2 RESTRAINTS 78 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 78 5.2.3 OPPORTUNITIES 79 5.2.3.1 Growing biotechnology industry 79 5.2.3.2 Emerging markets 79 5.2.3.3 Focus on developing human-aware AI systems 80 5.2.4 CHALLENGES 80 5.2.4.1 Limited availability of data sets 80 5.2.4.2 Lack of required tools and usability 80 6 INDUSTRY INSIGHTS 82 6.1 OVERVIEW OF KEY INDUSTRY TRENDS 82 6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY 82 FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET 83 6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI 84 FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET 84 6.2 SUPPLY CHAIN ANALYSIS 84 FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022) 85 6.3 PORTER’S FIVE FORCES ANALYSIS 85 TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 85 6.3.1 INTENSITY OF COMPETITIVE RIVALRY 85 6.3.2 BARGAINING POWER OF BUYERS 85 6.3.3 BARGAINING POWER OF SUPPLIERS 86 6.3.4 THREAT OF SUBSTITUTES 86 6.3.5 THREAT OF NEW ENTRANTS 86 6.4 ECOSYSTEM/MARKET MAP 86 FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM 86 6.5 TECHNOLOGY ANALYSIS 87 FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION 87 6.5.1 DRY LAB SERVICES 87 6.5.2 WET LAB SERVICES 90 6.5.2.1 Chemistry services 90 6.5.2.2 BIOLOGICAL SERVICES 91 6.5.2.2.1 Single-cell analysis 92 6.6 PRICING ANALYSIS 95 6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION 95 6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS 96 TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS 96 6.7 BUSINESS MODELS 96 FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS 97 FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS 97 FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME 98 6.8 CASE STUDY ANALYSIS 99 6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA 99 6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA 100 6.9 REGULATORY ANALYSIS 101 6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION 101 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 6.10 PATENT ANALYSIS 104 FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011–OCTOBER 2023) 104 FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011–OCTOBER 2023) 105 FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012–JULY 2023) 105 TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021–2023 106 6.11 KEY CONFERENCES & EVENTS (Q1 2023–Q2 2024) 108 6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 109 FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET 109 6.13 KEY STAKEHOLDERS & BUYING CRITERIA 109 6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 109 FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET 109 6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET 110 FIGURE 41 KEY BUYING CRITERIA FOR END USERS 110 6.14 AI-DERIVED CLINICAL ASSETS 110 TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY 110 6.15 UNMET NEEDS 120 6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY 120 6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY 121 6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY 122 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 123 7.1 INTRODUCTION 124 TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 124 7.2 SERVICES 124 7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH 124 TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 125 7.3 SOFTWARE 125 7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH 125 TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 126 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 127 8.1 INTRODUCTION 128 TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128 8.2 MACHINE LEARNING 128 TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 129 TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 129 8.2.1 DEEP LEARNING 130 8.2.1.1 Deep learning to see growing adoption in drug discovery 130 TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 130 8.2.2 SUPERVISED LEARNING 131 8.2.2.1 Applications in drug repositioning to drive market 131 TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 131 8.2.3 REINFORCEMENT LEARNING 132 8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption 132 TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 132 8.2.4 UNSUPERVISED LEARNING 133 8.2.4.1 Unpredictability to affect end-user adoption 133 TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 133 8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 134 TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 134 8.3 NATURAL LANGUAGE PROCESSING 135 8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH 135 TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 135 8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING 136 8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE 136 TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021–2028 (USD MILLION) 136 8.5 OTHER TECHNOLOGIES 137 TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 138 9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 139 9.1 INTRODUCTION 140 TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 140 9.2 ONCOLOGY 140 9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 140 TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 141 9.3 INFECTIOUS DISEASES 141 9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 141 TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 142 9.4 NEUROLOGY 143 9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 143 TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 143 9.5 CARDIOVASCULAR DISEASES 144 9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT 144 TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 144 TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 145 9.6 IMMUNOLOGY 145 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 145 TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146 9.7 METABOLIC DISEASES 146 9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION 146 TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 147 9.8 OTHER THERAPEUTIC AREAS 148 TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148 10 AI IN DRUG DISCOVERY MARKET, BY PROCESS 149 10.1 INTRODUCTION 150 FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022 150 TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 150 10.2 TARGET IDENTIFICATION & SELECTION 151 10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 151 TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 152 10.3 TARGET VALIDATION 152 10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE 152 TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 153 10.4 HIT IDENTIFICATION & PRIORITIZATION 154 10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION 154 TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 154 10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 155 10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE 155 TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021–2028 (USD MILLION) 156 10.6 LEAD OPTIMIZATION 156 10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION 156 TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 157 10.7 CANDIDATE SELECTION & VALIDATION 158 10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES 158 TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 159 11 AI IN DRUG DISCOVERY MARKET, BY USE CASE 160 11.1 INTRODUCTION 161 FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 161 TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 162 11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION 162 11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH 162 TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 163 11.3 UNDERSTANDING DISEASE 164 11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET 164 TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 165 11.4 SAFETY & TOXICITY 165 11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH 165 TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021–2028 (USD MILLION) 167 11.5 VACCINE DESIGN & OPTIMIZATION 167 11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH 167 TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 168 11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION 169 11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET 169 TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 170 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 171 12.1 INTRODUCTION 172 TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 172 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172 12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET 172 TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 173 TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 174 12.3 CONTRACT RESEARCH ORGANIZATIONS 175 12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 175 TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS 175 TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 177 12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD 177 TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS 177 TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 178 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 179 13.1 INTRODUCTION 180 TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021–2028 (USD MILLION) 180 13.2 NORTH AMERICA 180 13.2.1 NORTH AMERICA: RECESSION IMPACT 180 FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 181 TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182 TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 182 TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 182 TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 183 TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 183 TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 184 TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 184 TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 185 13.2.2 US 185 13.2.2.1 Strong economy and trend of early adoption of technologies to drive market 185 FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) 186 TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 186 TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 187 TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 187 TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 188 TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021–2028 (USD MILLION) 188 TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021–2028 (USD MILLION) 189 TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 189 TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 190 13.2.3 CANADA 190 13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth 190 TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 191 TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191 TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 192 TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 192 TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 193 TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 193 TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 194 13.2.4 MEXICO 194 13.2.4.1 Government initiatives to support market growth 194 TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 194 TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 195 TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 195 TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 196 TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 196 TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 197 TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 197 13.3 EUROPE 197 13.3.1 EUROPE: RECESSION IMPACT 198 TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 199 TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 199 TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 200 TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 200 TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 201 TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 201 TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 202 TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 202 13.3.2 UK 202 13.3.2.1 UK to hold largest share in Europe 202 TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 203 TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 204 TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 204 TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 205 TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 205 TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 206 TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 206 TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 207 13.3.3 GERMANY 207 13.3.3.1 Government support and favorable training programs to propel market growth 207 TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 208 TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 208 TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 209 TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209 TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 210 TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 210 TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 211 13.3.4 FRANCE 211 13.3.4.1 Strong government support and favorable strategies & initiatives to drive market 211 TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 211 TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 212 TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 212 TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 213 TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 213 TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 214 TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 214 13.3.5 ITALY 214 13.3.5.1 Strong pharmaceutical industry to support market growth 214 TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 215 TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 215 TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 216 TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 216 TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 217 TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 217 TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 218 13.3.6 REST OF EUROPE 218 TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 218 TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 219 TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 219 TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 220 TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 220 TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 221 TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 221 13.4 ASIA PACIFIC 222 13.4.1 ASIA PACIFIC: RECESSION IMPACT 222 TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 223 TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 223 TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 223 TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 224 TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 224 TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 225 TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 225 TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 226 13.4.2 JAPAN 226 13.4.2.1 Japan to dominate APAC market 226 TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 227 TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 227 TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 228 TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 228 TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 229 TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 229 TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 230 13.4.3 CHINA 230 13.4.3.1 Growing CMO market and cross-industry collaborations to drive market 230 TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 231 TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 231 TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 232 TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 232 TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 233 TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 233 TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 234 13.4.4 INDIA 234 13.4.4.1 Steady adoption of AI technologies to support market growth 234 TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 235 TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 235 TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 236 TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 236 TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 237 TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 237 TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 238 13.4.5 REST OF ASIA PACIFIC 238 TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 239 TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 239 TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 240 TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 240 TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 241 TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 241 TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 242 13.5 SOUTH AMERICA 242 13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION 242 13.5.2 SOUTH AMERICA: RECESSION IMPACT 243 TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 243 TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 243 TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 244 TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 244 TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 245 TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 245 TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 246
SummaryThe artificial intelligence (AI) in drug discovery market is projected to reach USD 4.9 billion by 2028 from USD 0.9 billion in 2023, at a CAGR of 40.2% during the forecast period. AI expedites the identification and validation of potential drug targets by analyzing intricate biological data. This accelerates the selection of biologically relevant targets for therapeutic interventions. AI techniques such as machine learning enable rapid analysis and decision-making, reducing the time and resources required for drug discovery processes. This efficiency gains a competitive edge in the fast-paced pharmaceutical landscape. Therefore, aforementioned factors will drive the growth of this market. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth to a certain extent over the forecast period. Table of Contents1 INTRODUCTION 381.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION 38 1.2.1 INCLUSIONS AND EXCLUSIONS 39 1.3 MARKET SCOPE 40 1.3.1 MARKET SEGMENTATION 40 FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION 40 1.3.2 REGIONAL SCOPE 41 1.3.3 YEARS CONSIDERED 41 1.3.4 CURRENCY CONSIDERED 42 TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 42 1.4 STAKEHOLDERS 42 1.5 SUMMARY OF CHANGES 43 1.5.1 RECESSION IMPACT 44 2 RESEARCH METHODOLOGY 45 2.1 RESEARCH DATA 45 FIGURE 2 RESEARCH DESIGN 45 2.2 SECONDARY SOURCES 46 2.2.1 KEY DATA FROM SECONDARY SOURCES 47 2.3 PRIMARY DATA 47 2.3.1 PRIMARY SOURCES 48 2.3.1.1 Key data from primary sources 49 2.3.1.2 Key industry insights 50 2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 50 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION 50 2.4 MARKET SIZE ESTIMATION 51 FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 52 FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY 53 TABLE 2 FACTOR ANALYSIS 55 FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 56 FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 56 FIGURE 8 TOP-DOWN APPROACH 57 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 58 FIGURE 9 DATA TRIANGULATION METHODOLOGY 58 2.6 ASSUMPTIONS 59 2.6.1 MARKET SIZING ASSUMPTIONS 59 2.6.2 OVERALL STUDY ASSUMPTIONS 59 2.7 LIMITATIONS 60 2.8 RISK ASSESSMENT 60 TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET 60 2.9 RECESSION IMPACT ANALYSIS 61 TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 61 TABLE 5 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61 TABLE 6 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 62 3 EXECUTIVE SUMMARY 63 FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION) 63 FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 64 FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 64 FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION) 65 FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2023 VS. 2028 (USD MILLION) 66 FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 66 FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT 67 4 PREMIUM INSIGHTS 68 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET 68 FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET 68 4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE 69 FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD 69 4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69 FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028 69 4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022 70 FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022 70 4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING 70 FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028 70 4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 71 FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028 71 4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 71 FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028 71 4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS 72 FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028 72 4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE 72 FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD 72 4.10 AI IN DRUG DISCOVERY MARKET, BY END USER 73 FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028 73 5 MARKET OVERVIEW 74 5.1 INTRODUCTION 74 5.2 MARKET DYNAMICS 74 FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS 74 TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS 75 5.2.1 DRIVERS 75 5.2.1.1 Growing cross-industry collaborations and partnerships 75 TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021−2023) 76 5.2.1.2 Growing need to reduce time and cost of drug discovery and development 77 5.2.1.3 Patent expiry of several drugs 77 TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 78 5.2.2 RESTRAINTS 78 5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 78 5.2.3 OPPORTUNITIES 79 5.2.3.1 Growing biotechnology industry 79 5.2.3.2 Emerging markets 79 5.2.3.3 Focus on developing human-aware AI systems 80 5.2.4 CHALLENGES 80 5.2.4.1 Limited availability of data sets 80 5.2.4.2 Lack of required tools and usability 80 6 INDUSTRY INSIGHTS 82 6.1 OVERVIEW OF KEY INDUSTRY TRENDS 82 6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY 82 FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET 83 6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI 84 FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET 84 6.2 SUPPLY CHAIN ANALYSIS 84 FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022) 85 6.3 PORTER’S FIVE FORCES ANALYSIS 85 TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 85 6.3.1 INTENSITY OF COMPETITIVE RIVALRY 85 6.3.2 BARGAINING POWER OF BUYERS 85 6.3.3 BARGAINING POWER OF SUPPLIERS 86 6.3.4 THREAT OF SUBSTITUTES 86 6.3.5 THREAT OF NEW ENTRANTS 86 6.4 ECOSYSTEM/MARKET MAP 86 FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM 86 6.5 TECHNOLOGY ANALYSIS 87 FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION 87 6.5.1 DRY LAB SERVICES 87 6.5.2 WET LAB SERVICES 90 6.5.2.1 Chemistry services 90 6.5.2.2 BIOLOGICAL SERVICES 91 6.5.2.2.1 Single-cell analysis 92 6.6 PRICING ANALYSIS 95 6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION 95 6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS 96 TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS 96 6.7 BUSINESS MODELS 96 FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS 97 FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS 97 FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME 98 6.8 CASE STUDY ANALYSIS 99 6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA 99 6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA 100 6.9 REGULATORY ANALYSIS 101 6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION 101 6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 6.10 PATENT ANALYSIS 104 FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011–OCTOBER 2023) 104 FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011–OCTOBER 2023) 105 FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012–JULY 2023) 105 TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021–2023 106 6.11 KEY CONFERENCES & EVENTS (Q1 2023–Q2 2024) 108 6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 109 FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET 109 6.13 KEY STAKEHOLDERS & BUYING CRITERIA 109 6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 109 FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET 109 6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET 110 FIGURE 41 KEY BUYING CRITERIA FOR END USERS 110 6.14 AI-DERIVED CLINICAL ASSETS 110 TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY 110 6.15 UNMET NEEDS 120 6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY 120 6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY 121 6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY 122 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 123 7.1 INTRODUCTION 124 TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 124 7.2 SERVICES 124 7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH 124 TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 125 7.3 SOFTWARE 125 7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH 125 TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 126 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 127 8.1 INTRODUCTION 128 TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128 8.2 MACHINE LEARNING 128 TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 129 TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 129 8.2.1 DEEP LEARNING 130 8.2.1.1 Deep learning to see growing adoption in drug discovery 130 TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 130 8.2.2 SUPERVISED LEARNING 131 8.2.2.1 Applications in drug repositioning to drive market 131 TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 131 8.2.3 REINFORCEMENT LEARNING 132 8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption 132 TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 132 8.2.4 UNSUPERVISED LEARNING 133 8.2.4.1 Unpredictability to affect end-user adoption 133 TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 133 8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 134 TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 134 8.3 NATURAL LANGUAGE PROCESSING 135 8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH 135 TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 135 8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING 136 8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE 136 TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021–2028 (USD MILLION) 136 8.5 OTHER TECHNOLOGIES 137 TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 138 9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 139 9.1 INTRODUCTION 140 TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 140 9.2 ONCOLOGY 140 9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 140 TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 141 9.3 INFECTIOUS DISEASES 141 9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 141 TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 142 9.4 NEUROLOGY 143 9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 143 TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 143 9.5 CARDIOVASCULAR DISEASES 144 9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT 144 TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 144 TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 145 9.6 IMMUNOLOGY 145 9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 145 TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146 9.7 METABOLIC DISEASES 146 9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION 146 TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 147 9.8 OTHER THERAPEUTIC AREAS 148 TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148 10 AI IN DRUG DISCOVERY MARKET, BY PROCESS 149 10.1 INTRODUCTION 150 FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022 150 TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 150 10.2 TARGET IDENTIFICATION & SELECTION 151 10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 151 TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 152 10.3 TARGET VALIDATION 152 10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE 152 TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 153 10.4 HIT IDENTIFICATION & PRIORITIZATION 154 10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION 154 TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 154 10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 155 10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE 155 TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021–2028 (USD MILLION) 156 10.6 LEAD OPTIMIZATION 156 10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION 156 TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 157 10.7 CANDIDATE SELECTION & VALIDATION 158 10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES 158 TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 159 11 AI IN DRUG DISCOVERY MARKET, BY USE CASE 160 11.1 INTRODUCTION 161 FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 161 TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 162 11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION 162 11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH 162 TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 163 11.3 UNDERSTANDING DISEASE 164 11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET 164 TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 165 11.4 SAFETY & TOXICITY 165 11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH 165 TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021–2028 (USD MILLION) 167 11.5 VACCINE DESIGN & OPTIMIZATION 167 11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH 167 TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 168 11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION 169 11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET 169 TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 170 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 171 12.1 INTRODUCTION 172 TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 172 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172 12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET 172 TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 173 TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 174 12.3 CONTRACT RESEARCH ORGANIZATIONS 175 12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 175 TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS 175 TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176 12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 177 12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD 177 TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS 177 TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 178 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 179 13.1 INTRODUCTION 180 TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021–2028 (USD MILLION) 180 13.2 NORTH AMERICA 180 13.2.1 NORTH AMERICA: RECESSION IMPACT 180 FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 181 TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182 TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 182 TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 182 TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 183 TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 183 TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 184 TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 184 TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 185 13.2.2 US 185 13.2.2.1 Strong economy and trend of early adoption of technologies to drive market 185 FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) 186 TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 186 TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 187 TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 187 TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 188 TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021–2028 (USD MILLION) 188 TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021–2028 (USD MILLION) 189 TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 189 TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 190 13.2.3 CANADA 190 13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth 190 TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 191 TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191 TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 192 TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 192 TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 193 TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 193 TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 194 13.2.4 MEXICO 194 13.2.4.1 Government initiatives to support market growth 194 TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 194 TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 195 TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 195 TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 196 TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 196 TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 197 TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 197 13.3 EUROPE 197 13.3.1 EUROPE: RECESSION IMPACT 198 TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 199 TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 199 TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 200 TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 200 TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 201 TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 201 TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 202 TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 202 13.3.2 UK 202 13.3.2.1 UK to hold largest share in Europe 202 TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 203 TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 204 TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 204 TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 205 TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 205 TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 206 TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 206 TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 207 13.3.3 GERMANY 207 13.3.3.1 Government support and favorable training programs to propel market growth 207 TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 208 TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 208 TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 209 TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209 TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 210 TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 210 TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 211 13.3.4 FRANCE 211 13.3.4.1 Strong government support and favorable strategies & initiatives to drive market 211 TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 211 TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 212 TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 212 TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 213 TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 213 TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 214 TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 214 13.3.5 ITALY 214 13.3.5.1 Strong pharmaceutical industry to support market growth 214 TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 215 TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 215 TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 216 TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 216 TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 217 TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 217 TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 218 13.3.6 REST OF EUROPE 218 TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 218 TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 219 TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 219 TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 220 TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 220 TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 221 TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 221 13.4 ASIA PACIFIC 222 13.4.1 ASIA PACIFIC: RECESSION IMPACT 222 TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 223 TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 223 TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 223 TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 224 TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 224 TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 225 TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 225 TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 226 13.4.2 JAPAN 226 13.4.2.1 Japan to dominate APAC market 226 TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 227 TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 227 TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 228 TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 228 TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 229 TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 229 TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 230 13.4.3 CHINA 230 13.4.3.1 Growing CMO market and cross-industry collaborations to drive market 230 TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 231 TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 231 TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 232 TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 232 TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 233 TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 233 TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 234 13.4.4 INDIA 234 13.4.4.1 Steady adoption of AI technologies to support market growth 234 TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 235 TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 235 TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 236 TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 236 TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 237 TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 237 TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 238 13.4.5 REST OF ASIA PACIFIC 238 TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 239 TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 239 TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 240 TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 240 TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 241 TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 241 TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 242 13.5 SOUTH AMERICA 242 13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION 242 13.5.2 SOUTH AMERICA: RECESSION IMPACT 243 TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 243 TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 243 TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 244 TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 244 TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 245 TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 245 TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 246
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療/ヘルスケア)の最新刊レポート
MarketsandMarkets社のHealthcare IT分野での最新刊レポート
本レポートと同じKEY WORD(ai)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |